2026 brings significant changes to GLP-1 coverage for Medicare beneficiaries, but the situation is more nuanced than many sources suggest. Here's what's actually happening with GLP-1 medications under Medicare in 2026.
What Changed in 2026?
Important clarification: Medicare Part D does not broadly cover all GLP-1 medications for weight loss in 2026. Instead, there are two separate programs with different timelines and coverage:
- Medicare GLP-1 Bridge Program — A temporary 6-month program (July 1 – December 31, 2026) covering Wegovy and Zepbound only at $50/month
- BALANCE Model — A permanent coverage framework starting January 2027 (not all Part D plans are required to participate)
Medicare GLP-1 Bridge Program (July–December 2026)
The Medicare GLP-1 Bridge is a temporary program designed to provide short-term access to GLP-1 medications for obesity while the permanent BALANCE Model is being implemented.
What's Covered
| Medication | Indication | Copay | Duration |
|---|---|---|---|
| Wegovy (semaglutide 2.4mg) | Weight management | $50/month | July 1 – Dec 31, 2026 |
| Wegovy HD (semaglutide 7.2mg) | Weight management | $50/month | July 1 – Dec 31, 2026 |
| Zepbound (tirzepatide 15mg) | Weight management | $50/month | July 1 – Dec 31, 2026 |
What's NOT Covered for Weight Loss
- Ozempic (semaglutide): Covered for diabetes only, NOT for weight loss under the Bridge
- Rybelsus (oral semaglutide): Covered for diabetes only, NOT for weight loss under the Bridge
- Mounjaro (tirzepatide): Covered for diabetes only, NOT for weight loss under the Bridge
- Foundayo: Covered under Lilly's separate Medicare pricing commitment (see below), not the Bridge program
Eligibility Requirements
- Enrolled in a Medicare Part D prescription drug plan
- BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity
- No diagnosis of type 2 diabetes (for the weight loss indication)
Important: The Bridge program ends December 31, 2026. Patients will need to transition to the permanent BALANCE Model or other coverage options in 2027.
Which GLP-1 Medications Are Covered?
Coverage varies significantly depending on the program (Bridge vs. BALANCE vs. Lilly's commitment) and your specific Part D plan. Here's the breakdown:
Medicare GLP-1 Bridge (July–Dec 2026 Only)
The temporary Bridge program covers only Wegovy and Zepbound for weight management at $50/month. Not all Part D plans participate — check with your plan.
Permanent Coverage: BALANCE Model (Starting Jan 2027)
The permanent BALANCE Model for ongoing Medicare GLP-1 coverage begins January 2027. Key details:
- Not all Part D plans are required to participate — participation is voluntary
- Coverage will extend beyond the 6-month Bridge program
- Specific medications and copays will be determined by individual plans
Foundayo: Eli Lilly's Medicare Pricing Commitment
Separate from both the Bridge and BALANCE Model, Eli Lilly has committed to offering Foundayo at $50/month for Medicare Part D beneficiaries starting July 1, 2026. This is Lilly's own pricing program, independent of the Bridge.
Foundayo on Medicare: Eli Lilly's $50/Month Commitment
Important: Foundayo's $50/month Medicare pricing is separate from the Medicare GLP-1 Bridge program. The Bridge covers Wegovy and Zepbound; Foundayo's pricing comes from Eli Lilly's own commitment to Medicare beneficiaries.
- Effective date: July 1, 2026
- Copay: $50/month for Medicare Part D beneficiaries
- Scope: Eli Lilly's pricing commitment (not part of the temporary Bridge program)
- Availability: Through Medicare Part D plans that include Foundayo on their formulary
This Lilly commitment provides an alternative pathway for Medicare beneficiaries, independent of the Bridge program's limitations.
How to Get Medicare Coverage for GLP-1 Weight Loss Medications
Step 1: Verify Your Eligibility
- You must be enrolled in a Medicare Part D prescription drug plan (standalone PDP or Medicare Advantage with prescription coverage)
- You must meet the medical criteria: BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity
- Your prescriber must document the medical necessity in your medical record
Step 2: Check Your Plan's Formulary
- Call the number on your Part D plan card and ask: "Which GLP-1 medications for weight management are on your formulary?"
- Ask about tier placement (this affects your copay)
- Ask about prior authorization requirements
- Check Medicare.gov Plan Compare for formulary details
Step 3: Get a Prescription
- Schedule an appointment with your healthcare provider
- Discuss which GLP-1 medication is right for you
- Your provider will need to submit documentation of BMI, comorbidities, and prior lifestyle modification attempts
- For Foundayo, many providers can prescribe immediately given its favorable formulary placement
Step 4: If Prior Authorization Is Required
Some Part D plans require prior authorization (PA). Your prescriber's office handles this, but here's what's typically required:
- Documentation of BMI (measured in office)
- List of weight-related comorbidities
- Evidence of prior lifestyle modification (diet, exercise counseling)
- Clinical rationale for the specific medication prescribed
- PA decisions are typically made within 72 hours (24 hours for expedited requests)
If Your Coverage Is Denied: The Appeals Process
If your Part D plan denies coverage, you have the right to appeal. The process:
Level 1: Plan Redetermination
- File within 60 days of the denial notice
- Your prescriber should submit a letter of medical necessity
- Plan must respond within 7 days (72 hours if expedited)
- Success rate: Approximately 40–50% of first appeals are successful
Level 2: Independent Review Entity (IRE)
- If Level 1 is denied, you can appeal to an independent reviewer
- File within 60 days of Level 1 denial
- IRE must decide within 7 days
- Success rate: Approximately 50–60% of IRE appeals are successful when supported by strong clinical documentation
Tips for Successful Appeals
- Have your doctor submit the appeal — clinical documentation from a prescriber carries more weight than patient-initiated appeals
- Include all relevant clinical data: BMI measurements, comorbidity diagnoses, lab work, prior treatment attempts
- Cite clinical guidelines: Reference AMA, Endocrine Society, or AGA obesity treatment guidelines that support GLP-1 therapy
- Document why alternatives won't work: If the plan wants you to try a different medication first, explain why your prescribed medication is medically necessary
- Don't give up after one denial. The IRE (Level 2) overturns a significant percentage of plan-level denials
Choosing the Right Part D Plan for GLP-1 Coverage
If you're enrolling in Medicare or changing plans during open enrollment (October 15 – December 7), consider GLP-1 coverage in your decision:
- Use Medicare Plan Finder: Enter your medications at Medicare.gov to compare total out-of-pocket costs across plans
- Look for plans that list your preferred GLP-1 on Tier 3 or lower — Tier 4 and 5 (specialty tiers) have higher copays
- Check the coverage gap: With the Inflation Reduction Act's $2,000 annual out-of-pocket cap (fully implemented in 2025), your total Part D spending is capped regardless of drug costs
- Consider Medicare Advantage plans — some MA plans offer enhanced drug benefits with lower GLP-1 copays
The $2,000 Out-of-Pocket Cap
Thanks to the Inflation Reduction Act, Medicare Part D beneficiaries have a $2,000 annual out-of-pocket maximum for prescription drugs. This is critical for GLP-1 users because:
- Even if your GLP-1 copay is high (e.g., $200/month for Wegovy), you'll hit the $2,000 cap within 10 months
- After reaching the cap, you pay $0 for the remainder of the year
- The Medicare Prescription Payment Plan lets you spread costs evenly across 12 months — so instead of paying large copays early in the year, you can pay ~$167/month maximum
For Foundayo at $50/month, you'd pay $600/year — well under the cap and very manageable.
What About Medicaid?
Medicaid coverage for GLP-1 weight management medications varies dramatically by state:
- Some states cover anti-obesity medications under Medicaid formularies
- Many states still exclude weight loss medications from Medicaid coverage
- If you have dual eligibility (Medicare + Medicaid), Medicare Part D is typically the primary payer for prescription drugs
- Check with your state Medicaid office for specific coverage policies
IRA Price Negotiations: What to Expect in 2027
Ozempic and Wegovy are part of the Medicare drug price negotiation program under the Inflation Reduction Act. Key points:
- Prices take effect in 2027, not 2026
- Negotiated prices will apply to Medicare beneficiaries only
- The impact on commercial insurance prices is uncertain
- Zepbound and Foundayo are not yet subject to price negotiation (newer drugs)
For Medicare beneficiaries, the $50/month programs (Bridge for Wegovy/Zepbound, Lilly commitment for Foundayo) are the primary cost-saving mechanisms in 2026. Price negotiation results will become relevant in 2027.
Key Dates for 2026–2027
- July 1, 2026: Medicare GLP-1 Bridge begins (Wegovy + Zepbound at $50/mo)
- July 1, 2026: Foundayo $50/month Medicare pricing begins (Lilly's commitment)
- December 31, 2026: Medicare GLP-1 Bridge program ends
- January 2027: BALANCE Model for permanent Medicare GLP-1 coverage begins (not all plans required to participate)
- 2027: IRA negotiated prices for Ozempic/Wegovy take effect
- October 15 – December 7, 2026: Medicare Open Enrollment for 2027 plans — compare GLP-1 coverage under BALANCE Model
Important: Coverage Is Evolving
This is a rapidly changing landscape. Medicare Part D formularies, copays, and program details may change throughout 2026. Before making decisions based on this information:
- Check with your specific Part D plan — coverage and copays vary by plan
- Verify current program details — the Bridge is temporary; BALANCE Model details are still being finalized
- Consult your healthcare provider — they can help navigate coverage options and prior authorization requirements
- Monitor CMS announcements — updates on the BALANCE Model and IRA price negotiations
The Bottom Line
Medicare coverage for GLP-1 weight management medications in 2026 is more limited than many sources suggest. The temporary Bridge program (July–December 2026) covers Wegovy and Zepbound at $50/month, while Eli Lilly's separate commitment makes Foundayo available at $50/month starting July 2026. The permanent BALANCE Model begins in January 2027, but not all Part D plans are required to participate.
If you're on Medicare and considering GLP-1 therapy for weight loss, start by checking your plan's formulary and understanding which programs apply to you. The $50/month pricing for Wegovy, Zepbound (via Bridge), and Foundayo (via Lilly) represent significant improvements over paying full price — but coverage details vary by plan and will evolve through 2026–2027.
Sources
- Centers for Medicare & Medicaid Services. 2026 Medicare Part D Benefit Parameters. CMS.gov.
- CMS. "Medicare Prescription Drug Coverage of Anti-Obesity Medications." CMS Final Rule, 2025.
- Eli Lilly. "Foundayo Medicare Access Program." Lilly.com. 2026.
- Medicare.gov. Plan Compare Tool. Medicare.gov/plan-compare.
- Inflation Reduction Act. Part D Redesign: $2,000 Out-of-Pocket Cap. 2025–2026.
- KFF. "Medicare Part D Coverage of Weight Loss Drugs: What to Know." Kaiser Family Foundation. 2026.